Lower respiratory tract disorder
MONDO:0000270A disease involving the lower respiratory tract.
Also known as: disease of lower respiratory tract, disease or disorder of lower respiratory tract, disorder of lower respiratory tract, lower respiratory tract disease, lower respiratory tract disease or disorder
6951 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a second dose of steroids help premature babies breathe easier?
Disease control TerminatedThis study investigates whether giving a repeat course of betamethasone, a steroid, to pregnant women with preterm premature rupture of membranes (PPROM) can improve health outcomes for their premature babies. The main goal is to see if it shortens the baby's stay in the neonatal…
Phase: PHASE2, PHASE3 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to tame teen asthma that inhalers Can't control
Disease control TerminatedThis study tests an experimental drug called lebrikizumab in teenagers aged 12 to 17 whose asthma is not well controlled even with daily inhalers and a second medication. Participants receive either lebrikizumab or a placebo as a shot every 4 weeks for a year, while continuing th…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
Disease control TerminatedThis phase 2 trial tests whether a low dose of radiation (12 Gy in 3 fractions) combined with one dose of the immunotherapy drug durvalumab can boost the immune system's attack on lung cancer cells before surgery. The study enrolls people with stage 2 or 3 non-small cell lung can…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Placenta cells tested as COVID fighter – but trial stopped early
Disease control TerminatedThis early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.
Phase: PHASE1, PHASE2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Rollover study offers continued itacitinib access for chronic disease patients
Disease control TerminatedThis study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental drug aims to help COVID survivors breathe easier
Disease control TerminatedThis study tested a drug called deupirfenidone (LYT-100) in 185 adults who had breathing problems after a serious COVID-19 infection. Participants took either the drug or a placebo for several weeks to see if it improved their ability to walk. The trial was stopped early, so the …
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental cancer drug tested in early trial, but study stopped early
Disease control TerminatedThis early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Which oxygen strategy saves more lives? large trial puts three methods to the test
Disease control TerminatedThis trial tests whether high-flow nasal cannula oxygen or noninvasive ventilation works better than standard oxygen therapy for ICU patients with acute respiratory failure. About 1,470 adults will be randomly assigned to one of the three methods. The main goal is to see which ap…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a common antibiotic ease severe wheezing in young children?
Disease control TerminatedThis study investigates whether a 5-day course of oral azithromycin can reduce wheezing severity in preschool children (18 months to under 5 years) who come to the emergency department with a severe wheezing episode. Children are randomly assigned to receive either azithromycin o…
Phase: PHASE3 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug targets Hard-to-Treat tumors in early trial
Disease control TerminatedThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Lung cancer trial halted: did adding an Anti-Inflammatory drug help?
Disease control TerminatedThis phase 3 study tested whether adding canakinumab (an anti-inflammatory drug) to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer. The trial enrolled 673 participants but was terminated early, so the…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental HER2 cancer drug trial halted early
Disease control TerminatedThis was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to free severe asthma patients from daily steroids
Disease control TerminatedThis Phase 3 trial tests whether tezepelumab, an injectable biologic, can help adults with severe asthma reduce their daily dose of oral corticosteroids while still keeping their asthma under control. Participants receive either tezepelumab or a placebo for 28 weeks, and doctors …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer therapy targets tough tumors with radioactive precision
Disease control TerminatedThis early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for Hard-to-Treat lung cancer
Disease control TerminatedThis study tested a drug called poziotinib in 648 people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 mutations). The goal was to see if the drug could shrink tumors. The study was stopped early, but results showed some patients…
Phase: PHASE2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New cancer drug trial hopes to reawaken immune cells against tumors
Disease control TerminatedThis trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for stubborn lung infection? trial of epetraborole begins, then stops
Disease control TerminatedThis study tested an oral drug called epetraborole for people with a tough-to-treat lung infection called MAC lung disease. The trial aimed to see if adding epetraborole to standard treatment could improve symptoms and clear the infection. However, the study was terminated early,…
Phase: PHASE2, PHASE3 • Sponsor: AN2 Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental combo for Hard-to-Treat cancers shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…
Phase: PHASE1, PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lung cancer combo trial halted early: what happened?
Disease control TerminatedThis study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results ar…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental combo for lung cancer shows promise but study cut short
Disease control TerminatedThis phase 2 trial tested a combination of two drugs—NT-I7 and atezolizumab—in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors. However, the study was stopped early and only enrolled 33 out of …
Phase: PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
COVID-19 drug trial halted early: only 16 patients enrolled
Disease control TerminatedThis study tested an experimental drug called APX-115 in hospitalized patients with mild to moderate COVID-19. The goal was to see if it was safe and could help people recover faster. However, the trial was stopped early and only 16 people took part, so we don't have enough infor…
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental combo therapy shows promise in advanced cancers, but trial halted early
Disease control TerminatedThis study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a common chemo drug boost the benefits of palliative radiation for advanced cancer?
Disease control TerminatedThis phase 3 trial tests whether adding the chemotherapy drug carboplatin to standard palliative radiotherapy helps control tumor growth and reduce pain better than radiotherapy alone. The study includes adults with advanced lung or head and neck cancer who need palliative radiat…
Phase: PHASE3 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Lung cancer drug trial halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The stud…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental cancer drug study halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Lung cancer combo trial halted early: what we know
Disease control TerminatedThis early-phase study aimed to see if adding a special type of radiation therapy to the immunotherapy drug durvalumab could better control stage III lung cancer after standard treatment. Only 6 people took part before the study was stopped. The goal was to check safety and see i…
Phase: PHASE1, PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Heart drug fails to prove benefit for lung failure patients in early-stop trial
Disease control TerminatedThis study tested whether giving the heart medication metoprolol through a vein could help people with severe lung failure (ARDS) in the ICU. The goal was to see if it helped them breathe without a machine for more days. However, the trial was stopped early and only 14 people too…
Phase: PHASE3 • Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Electric field therapy plus immunotherapy tested for tough lung cancers
Disease control TerminatedThis study tested a wearable device that sends low-intensity electric fields to tumors, combined with the immunotherapy drug pembrolizumab, in people with advanced non-small cell lung cancer that had already been treated with chemotherapy and immunotherapy. The goal was to see if…
Phase: PHASE2 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Lung cancer gene therapy trial halted early
Disease control TerminatedThis early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was sa…
Phase: PHASE1 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental lung inflammation treatment trial shuts down after just one patient
Disease control TerminatedThis phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets common cancer mutation in early trial
Disease control TerminatedThis early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Lung cancer drug combo trial halted midway – what we know
Disease control TerminatedThis study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial was stopped early, so results are limited. It involved 102 adults who had not received prior chemotherap…
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Lung cancer drug combo study halted after just 4 patients
Disease control TerminatedThis study aimed to see if combining two drugs, bemcentinib and pacritinib, could help people with advanced lung adenocarcinoma that had stopped responding to other treatments. Only 4 patients were enrolled before the study was terminated early, so no conclusions can be drawn abo…
Phase: PHASE1, PHASE2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo before lung surgery shows promise but trial cut short
Disease control TerminatedThis pilot study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with radiation before surgery for stage III non-small cell lung cancer. Only 9 people took part, and the trial was stopped early. The goal was to see if this combination was safe an…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Inhaled treprostinil safety trial for PH-COPD ends early
Disease control TerminatedThis study looked at the long-term safety of an inhaled drug called treprostinil in people who have both pulmonary hypertension (high blood pressure in the lungs) and COPD. It included 41 adults who had already completed a previous study. The trial was terminated early, and the m…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Carbon monoxide as medicine? tiny trial tests inhaled gas for lung failure
Disease control TerminatedThis early-phase trial tested whether inhaling low doses of carbon monoxide could be safe for people with severe lung injury caused by sepsis. Only 5 participants were enrolled before the study was stopped early. The goal was to see if a personalized dosing formula could safely a…
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental lung cancer drug shows promise but trial halted early
Disease control TerminatedThis early-stage trial tested an experimental drug called BG-60366 in 33 people with advanced EGFR-mutant non-small cell lung cancer. The drug is designed to break down the faulty EGFR protein that drives cancer growth. The study aimed to check safety and find the right dose, but…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Pfizer's new cancer pill tested in advanced tumors – study halted early
Disease control TerminatedThis early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
Disease control TerminatedThis phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Mesothelioma radiation trial ends early – few answers found
Disease control TerminatedThis study looked at whether adding targeted radiation therapy to surgery and chemotherapy could help people with early-stage pleural mesothelioma live longer. Only 16 people took part before the trial was stopped early, so we don't have clear results. The approach aimed to kill …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cell therapy targets tough cancers, but trial ends early
Disease control TerminatedThis early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough lung cancer? trial tests targeted drug against chemo
Disease control TerminatedThis phase 3 trial compared an experimental drug called tusamitamab ravtansine to the chemotherapy docetaxel in 389 people with advanced non-small cell lung cancer that had a specific marker (CEACAM5). The study aimed to see if the new drug could slow cancer growth or improve sur…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control TerminatedThis study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Personalized cell therapy shows promise but trial ends early
Disease control TerminatedThis study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Lung cancer drug combo trial halted midway
Disease control TerminatedThis study tested a new combination of two drugs (ociperlimab and tislelizumab) against a standard drug (pembrolizumab) for people with advanced non-small cell lung cancer that had not been treated before. The trial aimed to see if the combo could help patients live longer or slo…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Lung cancer umbrella study tests multiple drug combos
Disease control TerminatedThis study tested several immunotherapy-based drug combinations in people with metastatic non-small cell lung cancer. It included two groups: those who had not received prior treatment and those whose cancer had worsened after standard therapy. The trial was terminated early, so …
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immune cell rescue after radiation shows promise in early cancer trial
Disease control TerminatedThis study tested whether giving patients their own immune cells (called lymphocytes) after chemotherapy and radiation could help their immune system recover faster. It included 19 adults with lung or esophageal cancer. The treatment was designed to reduce a common side effect of…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Early trial of experimental cancer combo halted after just 6 patients
Disease control TerminatedThis early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental lung cancer combo trial halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called Debio 0123 combined with standard chemotherapy (carboplatin and etoposide) in 34 adults with small cell lung cancer that had returned after prior treatment. The main goal was to find a safe dose and check for side effects.…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a cholesterol drug boost immunotherapy in lung cancer?
Disease control TerminatedThis study tested whether adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) is safe and helps the immune system fight advanced non-small cell lung cancer. It included 19 people with newly diagnosed metastatic lung cancer who had …
Phase: PHASE2 • Sponsor: Eziafa Oduah, MD, PhD, MPH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lung cancer combo trial halted after just one patient
Disease control TerminatedThis phase 2 study tested the drug durvalumab (Imfinzi) combined with two different schedules of stereotactic radiation for people with advanced non-small cell lung cancer. The goal was to see if the combination improved quality of life and controlled tumor growth. However, the t…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Laser vs. balloon: which works best for narrowed windpipe?
Disease control TerminatedThis study compared two procedures—laser resection and dilatation—for treating benign (non-cancerous) narrowing of the windpipe. The goal was to see which one better prevents the narrowing from coming back within two years. The trial was terminated early, so the results are limit…
Phase: NA • Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Promising fungal infection treatment study halted early
Disease control TerminatedThis study tested whether adding an inhaled medication (PC945) to standard antifungal drugs could help people with a severe, hard-to-treat lung fungal infection called invasive pulmonary aspergillosis. The trial aimed to see if the combination improved survival and response by da…
Phase: PHASE3 • Sponsor: Pulmocide Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Lung cancer immune cell therapy study stopped early after just 2 patients
Disease control TerminatedThis study tested a treatment called GT201, which uses immune cells taken from a patient's own tumor to attack advanced lung cancer. It was designed for adults aged 18-70 with non-small cell or small cell lung cancer that had stopped responding to standard treatments. The study w…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Lung cancer drug combo trial halted early
Disease control TerminatedThis study tested a new combination of cancer drugs (bemarituzumab plus anlotinib) against a standard treatment (tislelizumab) for people with extensive-stage small cell lung cancer. The goal was to see if the new combo could delay cancer growth or improve survival. However, the …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer immune cell trial halted after just 2 patients
Disease control TerminatedThis early trial tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back along with an immune-boosting drug called teraplizumab. The goal was to see if this combination is safe and tolerable for people with advanced non-smal…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Cancer drug combo trial halted early after only 13 patients
Disease control TerminatedThis study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with a specific gene change (NRG1 fusion) and advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the…
Phase: PHASE2 • Sponsor: Partner Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer combo trial halted early – too few patients to draw conclusions
Disease control TerminatedThis phase 2 study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was stopped early after enrolling only 9 participants, so we cannot tell if the combination is safe or effect…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Personalized lung cancer trial halted early, but shows promise
Disease control TerminatedThis study tested whether matching specific targeted drugs to the genetic changes in a person's ALK-positive lung cancer could improve treatment. It included 10 adults with advanced non-small cell lung cancer that had already been treated. The trial was stopped early due to low e…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pfizer's new cancer drug combo tested in tiny early trial
Disease control TerminatedThis early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental cell therapy for advanced lung cancer shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the …
Phase: PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo for tough cancers shows early promise, but trial halted
Disease control TerminatedThis early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal wa…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental cancer drug AUR106 tested in humans for first time
Disease control TerminatedThis early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Early lung cancer drug combo trial halted after just 6 patients
Disease control TerminatedThis study looked at giving the immunotherapy drug pembrolizumab (Keytruda) alone or with chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. However, the trial was s…
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control TerminatedThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase: PHASE1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cancer pill shows early promise, but trial halted
Disease control TerminatedThis early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cancer drug GEN1047 tested in humans – study halted early
Disease control TerminatedThis study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Lung cancer radiation trial halted early – only 6 patients enrolled
Disease control TerminatedThis early-phase trial tested whether giving a higher radiation dose directly to the lung tumor (while keeping standard doses to surrounding areas) is safe for people with non-small cell lung cancer. Only 6 participants were enrolled before the study was terminated. The goal was …
Phase: PHASE1, PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise in tough lung cancers
Disease control TerminatedThis study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Microwave probe aims to clear cancer-blocked airways, but study halted early
Disease control TerminatedThis study tested a new microwave device used through a thin tube to destroy tumors blocking the main airways in people with lung cancer. Only 3 patients were enrolled before the study was stopped. The goal was to see if the device could safely and effectively open the airway.
Phase: NA • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cancer combo trial ends before it begins: only one patient enrolled
Disease control TerminatedThis early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
BioNTech's RNA cancer therapy trial halted early
Disease control TerminatedThis study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental cancer pill tested in advanced tumors – trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called DCC-3116 (inlexisertib) in 91 people with advanced or metastatic solid tumors that have RAS/MAPK pathway mutations. The drug was given alone or combined with other targeted therapies. The study aimed to find safe doses and check for…
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Inhaled drug aims to save transplanted lungs from silent threat
Disease control TerminatedThis study tested an inhaled form of cyclosporine A (L-CsA) added to standard care for lung transplant patients with bronchiolitis obliterans syndrome (BOS), a condition that scars the lungs' small airways. The goal was to see if the treatment could slow the decline in lung funct…
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug hope for lung damage after transplant falls short
Disease control TerminatedThis study tested the drug ruxolitinib to treat early lung damage in children and adults who had a stem cell transplant. Lung problems like bronchiolitis obliterans can be serious and hard to detect early. The trial aimed to see if adding ruxolitinib to standard care could improv…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Lung cancer drug trial halted: olaparib shows no clear benefit in maintenance therapy
Disease control TerminatedThis study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Lung cancer pilot: High-Dose radiation before surgery tested
Disease control TerminatedThis early-phase pilot study looked at combining stereotactic body radiation therapy (SBRT) with surgery for patients with stage I-IIIA non-small cell lung cancer. SBRT delivers very high, precise radiation doses to the tumor while sparing healthy tissue. The study aimed to check…
Phase: EARLY_PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental lung cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if the drug was safe and could shrink tumors. The trial was stopped early, and only 19 pe…
Phase: PHASE1, PHASE2 • Sponsor: Therapex Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental lung cancer drug trial halted early – only 18 patients enrolled
Disease control TerminatedThis early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental cancer drug CPO-100 trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental lung cancer vaccine trial halted early
Disease control TerminatedThis early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo targets lung cancer that resists immunotherapy
Disease control TerminatedThis early-stage trial tested a combination of two treatments—atezolizumab (an immunotherapy drug) and interleukin-12 gene therapy (which uses a virus to deliver a gene that boosts the immune system)—in 13 people with advanced non-small cell lung cancer that had worsened after in…
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New asthma pill shows promise in early trial
Disease control TerminatedThis phase 2 study tested an experimental oral drug called RPT193 in 38 adults with moderate-to-severe asthma that was not fully controlled by standard inhalers. The goal was to see if RPT193 could reduce asthma attacks and improve lung function. The trial was terminated early, s…
Phase: PHASE2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple gas stop COVID-19 from getting worse?
Disease control TerminatedThis study tested whether breathing in nitric oxide gas could keep mild-to-moderate COVID-19 from becoming severe. Researchers enrolled 62 hospitalized adults who were breathing on their own. The goal was to see if the gas reduced the need for a breathing tube. The trial was stop…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Pfizer tests new drug combo for advanced cancers – but study ends early
Disease control TerminatedThis early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental KRAS blocker tested in advanced cancers – trial halted early
Disease control TerminatedThis early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug auxora tested in critical COVID-19 lung patients
Disease control TerminatedThis small Phase 2 trial tested an experimental drug called Auxora in 10 patients with critical COVID-19 pneumonia who were on ventilators. The goal was to see how the drug affected immune cells in the lungs and to check its safety. The study was terminated early, so results are …
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Early trial of PF-08046031 for advanced cancers ends early
Disease control TerminatedThis early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findin…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo targets brain metastases in advanced cancers
Disease control TerminatedThis study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental lung cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested a new immunotherapy drug called vudalimab combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It compared this combination to the standard treatment of pembrolizumab plus chemotherapy. The study was terminated ear…
Phase: PHASE1, PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Oxygen debate: lower levels may be safer for COPD patients
Disease control TerminatedThis study aimed to find the best oxygen level for people hospitalized with a sudden worsening of COPD. It compared giving enough oxygen to reach 88-92% saturation versus over 94%. The trial was stopped early after only 23 people took part, so the results are not strong enough to…
Phase: PHASE4 • Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for lung scarring? trial of GSK3915393 cut short
Disease control TerminatedThis study tested a new medicine, GSK3915393, in 158 people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The goal was to see if the drug could slow lung function decline compared to a placebo. The trial was termin…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Lung cancer immunotherapy cocktail shows promise but trial halted early
Disease control TerminatedThis phase 2 trial tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in 50 people with early-stage non-small cell lung cancer that could be surgically removed. The goal was to see if the treatment shrank tumors before surgery and prevented…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Vitamin c and immunotherapy combo trial for lung cancer ends early after just one patient
Disease control TerminatedThis very early trial aimed to see if adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune response against non-small cell lung cancer before surgery. It planned to enroll people with early-stage lung cancer, but was terminated after only one par…
Phase: PHASE1 • Sponsor: William Zeitler • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental combo for tough lung cancer hits dead end
Disease control TerminatedThis study tested two immunotherapy drugs, AK119 and AK112, with or without chemotherapy, in 59 people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) that had stopped responding to standard targeted pills. The goal was to see if the combination was …
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Targeted pill shows promise for rare lung cancer, but trial stopped early
Disease control TerminatedThis phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental cancer drug DCC-3084 tested in early trial
Disease control TerminatedThis early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug (BMS-986218) plus nivolumab and targeted radiation in people with advanced solid tumors that had spread. The goal was to see if this combination could help the immune system fight cancer better. Only 13 people took part before the study was stopped ea…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Probiotic study for diabetes and COPD halted early
Disease control TerminatedThis study looked at whether taking probiotics alongside regular treatment could help lower blood sugar and improve lung function in people with both type 2 diabetes and chronic obstructive pulmonary disease (COPD). The trial planned to enroll 30 adults aged 50-85, but it was ter…
Phase: NA • Sponsor: Glac Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cancer drug shows early promise, but trial cut short
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug fails to show benefit in severe COVID-19 pneumonia trial
Disease control TerminatedThis study tested whether adding reparixin to standard care could prevent death or the need for a breathing machine in 414 hospitalized adults with COVID-19 or other pneumonia. The trial was stopped early. Researchers compared reparixin to a placebo to see if it reduced severe ou…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New cancer drug BGB-24714 tested in early trial for solid tumors
Disease control TerminatedThis early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Targeted drug poziotinib tested in rare lung cancer mutations
Disease control TerminatedThis phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Lung cancer combo therapy trial stopped early
Disease control TerminatedThis study tested giving the immunotherapy drug nivolumab along with chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if this combination could shrink tumors enough to leave less than 10% cancer cells in th…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Grape seed extract studied as Pre-Surgery lung cancer treatment
Disease control TerminatedThis study tested a special grape seed extract (leucoselect phytosome) given before surgery to people with early-stage lung cancer. The goal was to see if it was safe and could slow tumor growth. Only 6 people took part, and the study was stopped early, so we don't have clear ans…
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Early trial of experimental cancer combo halted after 21 patients
Disease control TerminatedThis early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cancer drug QEQ278 tested in Early-Stage trial
Disease control TerminatedThis early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Asthma drug tested for stubborn nasal polyps – trial cut short
Disease control TerminatedThis phase 3 study tested the drug benralizumab in 295 adults with severe nasal polyps and eosinophilic chronic sinusitis. Participants received injections of benralizumab or a placebo every 4 to 8 weeks for about a year. The goal was to see if the drug could shrink polyps and im…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…
Phase: PHASE1 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to keep advanced lung cancer in check
Disease control TerminatedThis study looked at whether a combination of two drugs, rucaparib and pembrolizumab, could help people with stage IV non-small cell lung cancer keep their cancer from growing after initial treatment. The study included 25 adults whose cancer had not gotten worse after standard c…
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control TerminatedThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising cancer combo trial halted after just 2 patients
Disease control TerminatedThis early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…
Phase: PHASE1, PHASE2 • Sponsor: Ariceum Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental combo for tough lung cancer hits early snag
Disease control TerminatedThis early-phase trial tested a combination of two immunotherapy drugs (atezolizumab and varlilumab) plus targeted radiation in 16 people with advanced non-small cell lung cancer that had stopped responding to standard treatment. The goal was to see if the triple therapy was safe…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can grid radiation revive immunotherapy in lung cancer?
Disease control TerminatedThis early study tested whether combining the immunotherapy drug durvalumab with a special type of radiation called grid therapy could help people with non-small cell lung cancer whose cancer had stopped responding to durvalumab alone. Only 4 patients were enrolled before the stu…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New COPD inhaler Add-On studied, but trial halted early
Disease control TerminatedThis study tested two doses of an inhaled drug called CHF6001 (Tanimilast) added to standard triple therapy in people with severe COPD and chronic bronchitis. The goal was to see if it could reduce the number of moderate or severe flare-ups over a year. The trial was terminated e…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Light therapy boosts immune attack on lung cancer? early trial halted
Disease control TerminatedThis early-phase trial tested whether a light-activated drug (photodynamic therapy) could help immunotherapy work better in patients with non-small cell lung cancer that has spread to the lining of the lung or with mesothelioma. Only 5 people took part, and the study was stopped …
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising combo for rare cancer mutation stalls as study ends early
Disease control TerminatedThis early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…
Phase: PHASE2 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Heat therapy for lung cancer: early trial ends early
Disease control TerminatedThis study looked at using a microwave ablation device to destroy lung tumors in people who could not have surgery or chose not to. It included 13 adults with non-small cell lung cancer or tumors that had spread to the lung. The treatment was given through a needle inserted into …
Phase: NA • Sponsor: Ethicon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Lung cancer drug trial halted early: what toripalimab Couldn't prove
Disease control TerminatedThis phase II trial tested whether the immunotherapy drug toripalimab could help patients with limited-stage small cell lung cancer stay cancer-free longer after standard chemoradiotherapy. The study planned to enroll 170 adults aged 18-75 who had not progressed after treatment. …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental cancer pill targets Hard-to-Treat tumors
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental combo for rare lung cancer shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the drug pembrolizumab (Keytruda) combined with targeted radiation (SBRT) in 5 people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The goal was to check safety and find the right dose. The study was terminated early…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug tested in people with advanced tumors
Disease control TerminatedThis early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Common diabetes and acne drugs studied for head and neck cancer treatment
Disease control TerminatedThis study tested whether metformin (a diabetes drug) and doxycycline (an antibiotic) could help treat head and neck cancer when taken before surgery. The trial aimed to see if these drugs could change certain proteins in the tumor's supportive tissue. Only 7 people took part bef…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Lung cancer trial adding radiation to immunotherapy halted early
Disease control TerminatedThis study looked at whether adding radiation to the chest could improve survival for people with extensive-stage small-cell lung cancer who were already receiving chemotherapy and immunotherapy. The trial planned to enroll 239 participants but was terminated early. The main goal…
Phase: PHASE3 • Sponsor: Norwegian University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental combo for advanced lung cancer shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the combination of the immunotherapy drug pembrolizumab (Keytruda) with precise, high-dose radiation (SBRT) in patients with advanced non-small cell lung cancer that had progressed after chemotherapy. The study aimed to find the safest radiation dose…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
HIV cancer hope: immune combo shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Rapid test plus targeted antibiotic shows promise for tough infections in blood cancer patients
Disease control TerminatedThis study tested whether the antibiotic ceftolozane-tazobactam, guided by a rapid molecular test, could effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. The 17 participants received the antibiotic t…
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Promising combo trial for brain metastases halted after just 3 patients
Disease control TerminatedThis trial tested two immune-boosting drugs, tiragolumab and atezolizumab, with or without chemotherapy, in people with non-small cell lung cancer that had spread to the brain. The goal was to see if the combination could control the brain tumors and delay the need for radiation.…
Phase: PHASE2 • Sponsor: Liza Villaruz, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, …
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Lung fibrosis drug study halted early
Disease control TerminatedThis study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. It included 46 adults aged 40 and older with mild to moderate IPF. The main goal was to see if the treatments improved lung function, mea…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Bronchiectasis drug trial halted early – what we know
Disease control TerminatedThis trial tested the drug Cayston (aztreonam lysine) in adults with bronchiectasis, a chronic lung disease causing cough and infections. The goal was to see if it could safely delay or reduce lung flare-ups. However, the study was stopped early and only enrolled 34 people, so we…
Phase: PHASE4 • Sponsor: University of Dundee • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Chemo-Free hope for lung cancer: new drug combo tested
Disease control TerminatedThis study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced non-small cell lung cancer that had spread. The goal was to see if these drugs could control the cancer without needing chemotherapy. Only 5 people took part before the study was stopped …
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Immunotherapy combo studied for advanced lung cancer, but trial cut short
Disease control TerminatedThis study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before th…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Cancer combo trial halted before full results
Disease control TerminatedThis early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Lung cancer combo trial halted early – what we know
Disease control TerminatedThis early-phase trial tested the immunotherapy drug sasanlimab combined with various targeted therapies in 34 people with advanced non-small cell lung cancer. The goal was to check safety and find the right doses. However, the study was terminated early, meaning we have limited …
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immunotherapy combo studied for rare lung cancer, trial stopped early
Disease control TerminatedThis study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental drug aims to keep viral pneumonia patients out of hospital
Disease control TerminatedThis Phase 2 trial tested the drug silmitasertib (CX-4945) plus standard care in adults with pneumonia caused by COVID-19 or influenza. The goal was to see if the drug could reduce the need for hospitalization or prevent death. The study planned to enroll 120 people but was termi…
Phase: PHASE2 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental cell therapy for resistant lung cancer tested in tiny trial
Disease control TerminatedThis early-phase trial tested a new treatment called C-TIL051 for people with advanced non-small cell lung cancer that no longer responded to standard immunotherapy. The treatment involved taking immune cells from the patient's tumor, growing them in a lab, and infusing them back…
Phase: PHASE1 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a drug make milk allergy therapy safer and more effective?
Disease control TerminatedThis study tested whether adding dupilumab (a drug that reduces allergic reactions) to milk oral immunotherapy (gradually eating small amounts of milk) helps people with cow's milk allergy tolerate more milk with fewer side effects. The trial included 33 people aged 4 to 50 years…
Phase: PHASE2 • Sponsor: Andrew J Long, PharmD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Early antibiotics in ICU aspiration: small trial halted before answers
Disease control TerminatedThis study tested whether giving antibiotics early to ICU patients who may have inhaled stomach contents could prevent pneumonia and improve recovery. Only 5 patients were enrolled before the trial was stopped early. The results are too limited to draw any conclusions about wheth…
Phase: PHASE4 • Sponsor: UConn Health • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New breathing device could help COPD patients who reject standard machines
Disease control TerminatedThis study tested a high-flow nasal cannula device (Airvo) in COPD patients with high carbon dioxide levels who could not or would not use standard non-invasive ventilation. The goal was to see if the device improved blood gas levels and reduced flare-ups over one year. Only 3 pa…
Phase: NA • Sponsor: Turku University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Lung cancer combo trial halted early – only 5 patients tested
Disease control TerminatedThis study tested a combination of two drugs, HBI-8000 and pembrolizumab (Keytruda), in people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and could shrink tumors. However, the trial was stopped early after enrolling only 5 participan…
Phase: PHASE2 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New asthma treatment for kids who Don't respond to standard steroids?
Disease control TerminatedThis study tested whether a drug called tiotropium works as well as inhaled steroids for children aged 6 to 11 with mild asthma that is not linked to allergies. Many children with non-allergic asthma do not respond well to steroids, so researchers wanted to see if tiotropium alon…
Phase: PHASE2 • Sponsor: Nemours Children's Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New inhaler for COPD shows promise in early trial
Disease control TerminatedThis study tested an experimental inhaled drug called HRG2005 in people with moderate to severe chronic obstructive pulmonary disease (COPD). The goal was to see if it improves lung function compared to a standard treatment. About 82 participants were enrolled, but the study was …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Lung cancer combo trial halted early – what we know
Disease control TerminatedThis study tested a new pill (SLC-391) combined with an immunotherapy drug (pembrolizumab) in 36 adults with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combination could shrink tumors. The trial was terminated early, so re…
Phase: PHASE1, PHASE2 • Sponsor: SignalChem Lifesciences Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New inhaler aims to tame uncontrolled asthma Flare-Ups
Disease control TerminatedThis study tested an experimental inhaler (CHF6001) added to standard asthma medicines in 517 adults with uncontrolled asthma. The goal was to see if it could reduce severe asthma attacks over one year. The trial was stopped early, and results are not yet available.
Phase: PHASE2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Asthma drug safety check: dexpramipexole under Long-Term review
Disease control TerminatedThis study looked at the long-term safety of dexpramipexole in adults with severe eosinophilic asthma. Participants had already completed earlier phase 3 trials. The goal was to track side effects and asthma control over time. However, the study was terminated early, which may li…
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Asthma drug trial halted midway: what it means for patients
Disease control TerminatedThis study tested a daily pill called dexpramipexole in 654 people with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. The goal was to see if the drug could reduce severe asthma attacks over a year. However, the trial was terminat…
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Lung cancer drug trial halted early: what we know
Disease control TerminatedThis early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a powerful chemotherapy directly to cancer cells…
Phase: PHASE1 • Sponsor: Mythic Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Lung cancer combo trial halted after just 5 patients
Disease control TerminatedThis study tested a combination of two targeted drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their c…
Phase: PHASE1, PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
COPD drug trial halted: new Add-On therapy falls short
Disease control TerminatedThis study tested an inhaled drug called CHF6001 (Tanimilast) in people with COPD and chronic bronchitis who were already on triple therapy. The goal was to see if adding this drug could reduce flare-ups. The trial was stopped early and involved about 4,700 participants.
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo may help more lung cancer patients get Life-Extending radiation
Disease control TerminatedThis study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung tumors enough to allow patients to then receive radiation therapy. The trial was stopped early after enrolling only 10 people, so results are limited. The…
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Asthma drug trial halted: Dexpramipexole's promise unfulfilled
Disease control TerminatedThis Phase 3 trial tested dexpramipexole, an oral drug, in over 1,000 people with severe eosinophilic asthma that was not well controlled by standard treatments. The goal was to see if it could reduce severe asthma attacks over a year. However, the study was terminated early, so …
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can an antiviral drug help sepsis patients breathe on their own sooner?
Disease control TerminatedThis phase 3 trial tested whether the antiviral drug ganciclovir could prevent reactivation of cytomegalovirus (CMV) in adults with sepsis who needed a breathing machine. The study enrolled 205 CMV-positive patients in the ICU with acute respiratory failure. Participants received…
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy plus radiation for early lung cancer: trial halted early
Disease control TerminatedThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Promising IPF drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called HZN-825 in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. The trial aimed to see if the drug could slow the decline in lung function over a year. About 153 adults with IP…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New lung cancer drug shows promise in Head-to-Head trial
Disease control TerminatedThis study tested a new drug called BAT3306 against the standard treatment Keytruda, both combined with chemotherapy, in 162 people with advanced non-small cell lung cancer. The goal was to see if BAT3306 works as well as Keytruda in shrinking tumors. The trial was stopped early,…
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental cancer drug TAK-186 tested in patients with advanced tumors
Disease control TerminatedThis study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Lung disease drug trial in kids halted early
Disease control TerminatedThis study tested whether hydroxychloroquine could help children with a rare lung condition called interstitial lung disease. About 35 children were planned to take either the drug or a placebo to see if their oxygen levels or breathing improved. The trial was stopped early, so r…
Phase: PHASE2 • Sponsor: Matthias Griese • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Cancer drug combo trial halted early – what we know
Disease control TerminatedThis trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental COVID-19 drug fails to prevent respiratory failure in High-Risk patients
Disease control TerminatedThis study tested an experimental drug called ABX464 in 509 high-risk COVID-19 patients aged 65 and older, or those 18+ with risk factors like obesity or diabetes. The goal was to see if the drug could reduce inflammation and prevent the need for high-flow oxygen or a breathing m…
Phase: PHASE2, PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Robot-Assisted heat treatment for lung tumors tested – but study stopped early
Disease control TerminatedThis study tested a new way to treat lung tumors that have spread from other cancers. Doctors used a robotic bronchoscope to guide a microwave probe directly into the tumor and heat it to destroy the cancer cells. The study planned to enroll more people but was stopped early afte…
Phase: NA • Sponsor: Ethicon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Cancer-Fighting virus injected directly into tumors shows promise in early trial
Disease control TerminatedThis early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Lung cancer combo trial halted early – what we know
Disease control TerminatedThis study tested whether adding bintrafusp alfa (an immunotherapy) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer who have already tried other treatments. Only 10 people took part before the study was stopped early. The goal was to see…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Lung cancer combo trial halted early: what we know
Disease control TerminatedThis study looked at whether adding a single dose of radiation to the immunotherapy drug atezolizumab could help people with advanced lung cancer whose disease had gotten worse after both chemotherapy and another type of immunotherapy. The trial planned to include 12 adults with …
Phase: PHASE2 • Sponsor: Oncology Institute of Southern Switzerland • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental cancer drug study halted early
Disease control TerminatedThis study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…
Phase: PHASE1, PHASE2 • Sponsor: Shasqi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New inhaled drug aimed at stubborn lung infection shows promise, but trial halted early
Disease control TerminatedThis phase 3 study tested an inhaled form of the antibiotic clofazimine added to standard therapy for people with MAC lung disease that did not respond to previous treatment. The goal was to see if the drug could clear the infection from sputum cultures and improve quality of lif…
Phase: PHASE3 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New MRI-Guided radiation shows promise for Hard-to-Treat lung tumors
Disease control TerminatedThis study tested a new way to deliver radiation therapy for central lung tumors using MRI guidance. The goal was to see if it is safe and can control tumors better than standard CT-guided radiation. Only 3 people took part before the study was stopped early.
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental lung cancer drug MGY825 tested in early trial
Disease control TerminatedThis early-phase study tested an investigational drug called MGY825 in 41 adults with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2/KEAP1/CUL3 mutations). The main goal was to check the drug's safety and find the right dose. The study was terminate…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug tested for rare lung condition after transplant
Disease control TerminatedThis early-stage study tested the safety of a drug called itacitinib in 8 adults who developed bronchiolitis obliterans syndrome (a type of lung scarring) after receiving a stem cell transplant from a donor. The goal was to see if the drug could help control the lung disease by b…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer-Fighting super cells tested in solid tumors – study halted early
Disease control TerminatedThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…
Phase: PHASE1, PHASE2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New inhaled therapy targets mucus in asthma and COPD – but trial halted early
Disease control TerminatedThis early-phase trial tested an inhaled drug called ARO-MUC5AC in healthy volunteers and people with asthma or COPD. The goal was to see if it is safe and how it affects lung function by targeting mucus production. The study was terminated early, so we have less information than…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Lung cancer maintenance combo trial stopped early
Disease control TerminatedThis study tested whether adding the drug vorolanib to standard maintenance therapy with atezolizumab could help people with extensive-stage small cell lung cancer stay cancer-free longer after initial chemotherapy. Only 11 participants were enrolled before the study was terminat…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug targets Hard-to-Treat lung cancer
Disease control TerminatedThis study tested an experimental drug called REGN5093-M114, alone or with another drug, in people with advanced non-small cell lung cancer that has too much MET protein. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early, but the resu…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for brain metastases? study tests pembrolizumab combo
Disease control TerminatedThis study looked at whether adding the drug pembrolizumab to chemotherapy could help people with a type of lung cancer that has spread to the brain but isn't causing symptoms. The goal was to control the cancer in the brain and body while keeping quality of life. Only 3 people t…
Phase: PHASE2 • Sponsor: John L. Villano, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termin…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Lung cancer drug combo trial halted early
Disease control TerminatedThis study tested a new drug (tusamitamab ravtansine) combined with pembrolizumab and chemotherapy in 57 people with advanced non-squamous non-small-cell lung cancer that has a specific marker (CEACAM5). The goal was to see if the combination was safe and shrank tumors. The trial…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Lung cancer combo trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called bemcentinib added to standard chemotherapy and immunotherapy for people with advanced non-squamous lung cancer. The study aimed to check safety and find the right dose, but it was terminated early. Only 26 people took part, so we ca…
Phase: PHASE1, PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug trial for MET-Positive lung cancer halted early
Disease control TerminatedThis study tested an experimental drug called telisotuzumab vedotin for people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a MET gene change. The goal was to see if the drug could shrink tumors. The trial was stopped early and e…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Cancer cocktail trial halted early – what went wrong?
Disease control TerminatedThis study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug ZW171 tested in 32 patients, but study stopped early
Disease control TerminatedThis early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Early trial of experimental cancer drug halted; data still under review
Disease control TerminatedThis early-phase study tested a new drug called PF-07284890, alone or with another drug (binimetinib), in 65 people with advanced cancers that have a specific genetic change (BRAF V600 mutation), including cancers that spread to the brain. The trial was terminated early, but rese…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug itacitinib tested for lung transplant complication – study stopped early
Disease control TerminatedThis early-phase trial tested the drug itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a type of chronic lung rejection) after a double lung transplant. The goal was to see if itacitinib could safely improve lung function. However, the study was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental combo therapy for advanced cancer shows promise but trial ends early
Disease control TerminatedThis study tested a new treatment for people with non-small cell lung cancer or kidney cancer that had spread to up to six spots in the body. The treatment combined a special type of radiation therapy (PULSAR) with immunotherapy drugs (pembrolizumab or nivolumab), with or without…
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Lung cancer drug trial stopped early — too few patients to know if it works
Disease control TerminatedThis study tested the drug capmatinib in people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). The goal was to see if taking the drug before and after surgery could improve outcomes. However, the trial was stopped early after enroll…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Lung cancer combo trial halted after just 4 patients
Disease control TerminatedThis phase 2 study tested a combination of the targeted drug osimertinib (Tagrisso) plus standard chemotherapy as a first treatment for advanced non-small cell lung cancer with uncommon EGFR mutations. Only 4 participants were enrolled before the study was terminated, so no meani…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped e…
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Early cancer drug trial halted after just 3 patients
Disease control TerminatedThis early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental lung cancer combo trial ends early
Disease control TerminatedThis phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Personalized ventilation for ARDS: early trial halted, results uncertain
Disease control TerminatedThis study tested whether setting a ventilator based on each patient's lung volume could improve outcomes for people with moderate-to-severe acute respiratory distress syndrome (ARDS). The approach used a bedside measurement to tailor the pressure applied during breathing. Howeve…
Phase: PHASE3 • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental cancer cocktails show promise, but study halted early
Disease control TerminatedThis early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental cancer combo trial halted early – what we know
Disease control TerminatedThis early-phase trial tested an experimental drug called WJ05129, taken as a tablet, together with the chemotherapy drug paclitaxel in people with advanced solid tumors that had spread. The study aimed to find safe doses and check for side effects. Only 26 people were enrolled, …
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Junjing BioSciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control TerminatedThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug study halted early: what we know
Disease control TerminatedThis study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug for lung disease fails to reach goal
Disease control TerminatedThis study tested an experimental drug called QBW251 in 42 adults with bronchiectasis, a lung condition that causes mucus buildup and infections. The goal was to see if the drug could reduce bacteria in the lungs and improve symptoms like coughing and breathing. However, the stud…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Lung cancer drug cocktail trial ends early – what we know
Disease control TerminatedThis phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see i…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental cancer pill targets Hard-to-Treat gene mutations
Disease control TerminatedThis early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC
-
Mesothelioma drug trial halted early – what we know
Disease control TerminatedThis phase 2 trial tested whether the drug nintedanib could help people with malignant pleural mesothelioma keep their cancer from growing after initial chemotherapy. 37 patients were randomly assigned to receive either nintedanib or a placebo twice daily. The study was terminate…
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC
-
Experimental asthma drug briquilimab fails to reach Late-Stage testing
Disease control TerminatedThis Phase 1 trial tested a single dose of briquilimab in 17 adults with mild-to-moderate allergic asthma to see if it was safe and could reduce asthma attacks triggered by allergens. The study was terminated early, meaning it did not continue as planned. The main goal was to che…
Phase: PHASE1 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:40 UTC
-
Pfizer's new cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
Cancer combo trial halted early: what went wrong?
Disease control TerminatedThis early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:56 UTC
-
New hope against deadly molds? early trial cut short
Disease control TerminatedThis study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.
Phase: PHASE2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
Inhaler trial for Kids' lung decline after transplant ends early
Disease control TerminatedThis phase 3 trial tested whether a combination inhaler (fluticasone and salmeterol) could improve lung function in children aged 6–17 who had a drop in breathing capacity after a stem cell transplant. The study aimed to prevent bronchiolitis obliterans, a serious lung complicati…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC
-
Experimental HER2 drug trial halted early – what it means
Disease control TerminatedThis early-stage trial tested an experimental drug called SAR443216 in 44 adults with advanced HER2-expressing solid tumors (such as breast, lung, or gastric cancer) that had come back or stopped responding to standard treatments. The study aimed to find a safe dose and check for…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:22 UTC
-
Experimental cancer combo trial halted early – what it means for patients
Disease control TerminatedThis early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:13 UTC
-
Radiation and immunotherapy combo tested for lung cancer
Disease control TerminatedThis early-phase trial tested the safety of giving a precise form of radiation (SABR) either before or after the immunotherapy drug pembrolizumab in 13 people with metastatic non-small cell lung cancer. The goal was to see if the combination caused severe side effects and whether…
Phase: PHASE1 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated Jun 26, 2026 17:11 UTC
-
New drug namilumab tested for lung sarcoidosis – but trial halted early
Disease control TerminatedThis study tested namilumab, an experimental drug, in 107 people with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The trial was randomized and placebo-controlled, but it was terminated early. The goal was to see if namilumab could reduce the need for res…
Phase: PHASE2 • Sponsor: Kinevant Sciences GmbH • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
New lung cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug called WJ13405 in 14 people with advanced non-small cell lung cancer that had stopped responding to other treatments. The goal was to check safety, side effects, and how well the drug worked. However, the trial was terminated early, so results are lim…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Junjing BioSciences Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:57 UTC
-
Smart oxygen machine aims to get COPD patients out of hospital faster
Disease control TerminatedThis study tested a device called FreeO2 that automatically adjusts oxygen levels for people hospitalized with a COPD flare-up. The goal was to see if it could shorten hospital stays compared to manual oxygen adjustment by staff. Only 17 people took part, and the study was stoppe…
Phase: NA • Sponsor: Laval University • Aim: Disease control
Last updated Jun 26, 2026 14:17 UTC
-
Experimental combo for tough lung cancer shows early promise, but study halted
Disease control TerminatedThis early-phase trial tested an experimental antibody called hSTC810 combined with the chemotherapy drug paclitaxel in 10 adults with relapsed or refractory extensive-stage small cell lung cancer. The goal was to see if the combination is safe and helps shrink tumors or slow the…
Phase: PHASE1, PHASE2 • Sponsor: STCube, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC
-
New drug aimed at lung cancer shows promise in early trial
Disease control TerminatedThis study tested an experimental drug called MORAb-202 in 31 people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had gotten worse after other treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The …
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 14:01 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control TerminatedThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
New screening method aims to catch lung cancer earlier in asbestos workers
Diagnosis TerminatedThis study looked at whether analyzing sputum (phlegm) with automated cytometry, combined with low-dose CT scans and blood tests, could better detect lung cancer in workers heavily exposed to asbestos. The goal was to reduce false positives and improve early diagnosis. The trial …
Phase: PHASE3 • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Ultrasound vs x-ray: a new way to spot lung issues in sick babies?
Diagnosis TerminatedThis study looked at whether chest ultrasound could be as good as chest X-ray for finding lung complications in infants under 2 years old with bronchiolitis. Only 19 babies were enrolled before the study was stopped early. The goal was to see if ultrasound, which uses no radiatio…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Could a bronchoscope replace X-Rays for pneumothorax?
Diagnosis TerminatedThis study tested whether the ultrasound tip of an EBUS bronchoscope, placed on the chest, can detect pneumothorax (collapsed lung) as well as a standard ultrasound probe. Researchers enrolled 17 patients, including those with and without pneumothorax. The goal was to see if this…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Blood cell test aims to spot lung cancer sooner
Diagnosis TerminatedThis study tested whether a type of cell in the blood, called CAMLs, can help find early-stage lung cancer in people with suspicious lung nodules. Researchers planned to enroll 200 adults with nodules that had not yet been biopsied. The trial was terminated early, so results are …
Sponsor: Fox Chase Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
New screening tool could uncover thousands of undiagnosed lung cases
Diagnosis TerminatedThis study tested a French version of the CAPTURE tool, which uses a short questionnaire and a peak flow breath test, to find people with undiagnosed obstructive lung disease (like COPD). Over 1,000 adults aged 40 and older who had not been diagnosed with asthma or COPD took part…
Sponsor: Groupe Hospitalier du Havre • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New imaging tracer aims to spot COPD damage early
Diagnosis TerminatedThis study tested a radioactive tracer called Annexin to see if it can detect early lung damage in people with COPD and in smokers. Researchers compared scans from healthy non-smokers, healthy smokers, and people with moderate to severe COPD. The goal was to find a better way to …
Phase: PHASE2 • Sponsor: Columbia University • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
New laser imaging aims to spot lung cancer in real time
Diagnosis TerminatedThis study tested whether adding a special laser imaging technique (nCLE) and a dye (fluorescein) to a standard needle biopsy could help doctors diagnose lung cancer more accurately. The plan was to compare the combined approach to the standard biopsy alone in people with suspici…
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 26, 2026 18:31 UTC
-
Blood test may spot lung cancer without a needle biopsy
Diagnosis TerminatedThis study looked at whether a blood test (called a fluid biopsy) could help diagnose lung cancer. Researchers collected blood samples from 51 people who were either scheduled for a lung biopsy or had recently had one. The goal was to see if the blood test could accurately detect…
Sponsor: University of Southern California • Aim: Diagnosis
Last updated Jun 26, 2026 13:46 UTC
-
Breathing machine may ease lung risk for kids with sickle cell
Prevention TerminatedThis study tested whether a non-invasive breathing machine (ventilation) could prevent acute chest syndrome, a serious lung complication, in children with sickle cell disease who were hospitalized for severe pain. The standard prevention is spirometry, which requires active deep …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Could skipping the chest tube after lung surgery cut pain and hospital time?
Symptom relief TerminatedThis trial investigates whether removing the chest tube during thoracoscopic lung surgery, instead of leaving it in place afterward, leads to less pain and faster recovery. Participants undergoing elective wedge resection are randomly assigned to have the tube removed during surg…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Mucus-Busting asthma trial fizzles out
Symptom relief TerminatedThis small study tested whether adding n-acetylcysteine (NAC) to albuterol could improve lung function and reduce mucus plugs in people with moderate-to-severe asthma. Only 4 participants were enrolled before the trial was terminated early. The crossover design gave each person t…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Ultrasound-Guided breathing support tested for chest injuries
Symptom relief TerminatedThis study tested whether using lung ultrasound to adjust ventilator pressure could improve oxygen levels in people with blunt chest trauma. Nineteen adults with rib fractures or lung bruises who needed breathing support were enrolled. The trial was terminated early, so the findi…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Vitamin c trial for elderly pneumonia fizzles out
Symptom relief TerminatedThis study looked at whether giving vitamin C to elderly patients hospitalized with pneumonia could improve their breathing and daily function. Only 9 people took part before the study was stopped early. Because it was so small, we can't say if vitamin C helps or not.
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Step counts may predict trouble during lung cancer therapy
Symptom relief TerminatedThis study tested whether monitoring daily step counts in people with stage III non-small cell lung cancer during chemoradiotherapy helps doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the study was s…
Phase: NA • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Exercise program for advanced lung cancer patients shows promise
Symptom relief TerminatedThis study looked at whether a supervised exercise program is possible for people with advanced bronchial cancer or mesothelioma. The goal was to see if patients could complete at least 6 rehab sessions to help with weakness and poor quality of life caused by the disease and its …
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
App aims to ease cancer treatment for minorities
Symptom relief TerminatedThis study tested a mobile app called Apricity CARE to help ethnic and racial minority patients with non-small cell lung cancer report side effects from immunotherapy. The goal was to reduce treatment delays and hospital visits. The study was stopped early, but it aimed to improv…
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Sarcoidosis drug study halted after only 2 patients enrolled
Symptom relief TerminatedThis study tested whether Acthar gel could improve symptoms and lung function in people with sarcoidosis, a disease that causes inflammation in the lungs. Researchers also checked if a blood marker called CXCL9 could predict how well the treatment works. Only 2 people joined befo…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:27 UTC
-
Exercise study for advanced lung cancer falls short
Symptom relief TerminatedThis study looked at whether a program combining different types of exercise could help people with advanced lung cancer feel less tired, move better, and have a better quality of life. It was designed for adults with stage III or metastatic non-small cell lung cancer who were al…
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Breathing machine showdown: which mode helps obese patients best?
Symptom relief TerminatedThis study compared two types of non-invasive breathing support for people with sudden breathing failure who are obese or have sleep apnea. One machine automatically adjusts pressure and volume, while the other uses a fixed pressure setting. The goal was to see which method clear…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Chilly wash may stop biopsy bleeding
Symptom relief TerminatedThis study tested whether rinsing the lung with cold salt water before a biopsy could reduce bleeding and make slides easier to read. Only 6 adults having a lung ultrasound and biopsy took part. The study was stopped early, so results are limited.
Phase: NA • Sponsor: TriHealth Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Opioid trial for COPD breathlessness halted early
Symptom relief TerminatedThis study tested whether a low dose of fentanyl, a strong painkiller, placed under the tongue could help people with severe COPD feel less breathless during exercise. The trial planned to include 40 participants but was stopped early. Because it was terminated, we cannot draw cl…
Phase: PHASE2, PHASE3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
Can meal timing protect your brain during cancer treatment?
Symptom relief TerminatedThis study tested a text-message-based diet program called Txt4fasting for people with breast or lung cancer that spread to the brain. The goal was to see if eating only during certain hours could reduce thinking and memory problems after radiation. Only 1 person enrolled before …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Saline mist and chest taps: could this combo help sick babies breathe easier?
Symptom relief TerminatedThis study looked at whether giving infants with bronchiolitis a saltwater mist plus gentle chest tapping every 6 hours helps them get better faster. The trial included 75 babies under 2 years old who were in the hospital and needed extra oxygen. Unfortunately, the study was stop…
Phase: PHASE4 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
New COPD inhaler shows promise in tiny pilot study
Symptom relief TerminatedThis phase 2 pilot study tested a new dual bronchodilator inhaler called PT003 in 4 people with stable moderate-to-severe COPD. Researchers measured breathing patterns and lung function right after the first dose and again after 4 weeks of treatment. The goal was to see if PT003 …
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Breathing vest tested for hospital patients – but study stopped early
Symptom relief TerminatedThis study tested a negative pressure vest (Biphasic Cuirass Ventilation) to see if it works as well as standard breathing masks for patients hospitalized with acute hypercapnic respiratory failure (high carbon dioxide levels). The trial planned to enroll 50 adults, but it was te…
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New MRI technique aims to spare healthy lung during cancer radiation
Symptom relief TerminatedThis early-phase trial tested whether a special MRI scan using hyperpolarized xenon gas could help doctors plan radiation therapy for non-small cell lung cancer. The goal was to map which parts of the lung are working well so radiation can avoid them, potentially reducing side ef…
Phase: PHASE1 • Sponsor: Xemed LLC • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New pill aims to quiet debilitating cough in lung scarring disease
Symptom relief TerminatedThis study tested an experimental drug called BI 1839100 in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) who have a chronic cough. Participants took different doses of the drug or a placebo for 12 weeks. The goal was to see if the drug c…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Shock therapy for lungs? tiny TENS trial fizzles out
Symptom relief TerminatedThis study looked at whether a gentle electrical stimulation device (TENS) placed on the skin could help people with COPD exercise longer after a serious flare-up. The plan was to compare exercise time with and without TENS in a small group of patients. However, the study was sto…
Phase: NA • Sponsor: Groupe Hospitalier du Havre • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New study checks immunotherapy safety in elderly cancer patients
Symptom relief TerminatedThis study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-bei…
Phase: PHASE4 • Sponsor: Institut Paoli-Calmettes • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Asthma pill for kids shows promise in early trial
Symptom relief TerminatedThis study looked at how a new chewable asthma tablet called fevipiprant works in children aged 6 to 12. The goal was to measure the drug's levels in the body and check for safety. Only 11 children took part before the study was stopped early.
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Can rehab at home beat the clinic for COPD patients?
Symptom relief TerminatedThis study looked at whether doing breathing and exercise training at home works as well as doing it at a rehab center for people with chronic obstructive pulmonary disease (COPD). The goal was to see if home rehab could improve exercise tolerance just as much, while also being c…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Musical pacifier may help preemies with lung disease eat sooner
Symptom relief TerminatedThis study tested a special pacifier that plays music or a mother's voice when a baby sucks correctly. It aimed to help premature infants with chronic lung disease learn to feed by mouth more quickly. The trial enrolled 33 babies but was stopped early, so the results are not conc…
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Nasal High-Flow device tested for breathing trouble
Symptom relief TerminatedThis study tested a device that delivers warm, moist air through the nose to help people with breathing failure who did not have too much acid in their blood. The goal was to see if it could prevent their condition from getting worse. Only 16 people took part, and the study was s…
Phase: NA • Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Can acupuncture help COPD patients breathe easier?
Symptom relief TerminatedThis pilot study explored whether adding acupuncture to standard pulmonary rehabilitation can improve lung function, exercise tolerance, and quality of life in people with COPD. Thirteen adults took part, receiving either electro-acupuncture at specific points or a control acupun…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Can a smartphone app ease cancer treatment side effects?
Symptom relief TerminatedThis study tested whether a digital health app (Roche DPM Module) helps cancer patients manage symptoms and reduce healthcare visits while on systemic treatment. About 49 participants used the app alongside standard care. The trial was terminated early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Can bringing palliative care home ease suffering?
Symptom relief TerminatedThis study tested whether providing palliative care at home, through a team of doctors, nurses, social workers, and chaplains, could improve symptoms and quality of life for people with advanced cancer, heart failure, or COPD. The plan was to enroll over 1,100 patients, but the t…
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Hospital workout boost for COPD patients shows promise
Symptom relief TerminatedThis study looked at whether adding functional strength training and neuromuscular electrical stimulation to usual hospital care helps people with COPD exacerbations recover better. The 35 participants did exercises like sit-to-stand and received mild electrical pulses to their t…
Phase: NA • Sponsor: Hasselt University • Aim: Symptom relief
Last updated Jun 26, 2026 17:15 UTC
-
Can a common painkiller combo stop Post-Surgery confusion in seniors?
Symptom relief TerminatedThis study looked at whether giving elderly patients a combination of acetaminophen and ibuprofen (Maxigesic) during and after minimally invasive lung surgery could reduce the risk of postoperative delirium (sudden confusion). The trial planned to compare the drug group to a plac…
Phase: PHASE4 • Sponsor: Korea University Guro Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 14:17 UTC
-
Scientists seek 10 years of patient records to unlock asthma secrets
Knowledge-focused TerminatedThis study aims to collect up to 10 years of electronic medical records and a one-time questionnaire from over 1,100 asthma and COPD patients who previously took part in the Salford Lung Study. The goal is to better understand how these lung diseases progress and how treatments w…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New ventilation technique tested in ICU patients with severe lung failure
Knowledge-focused TerminatedThis trial tested a new way of using a breathing machine (flow-controlled ventilation) against the standard method (pressure-controlled ventilation) in 15 ICU patients with moderate to severe acute respiratory distress syndrome (ARDS). The goal was to see if the new method uses l…
Phase: NA • Sponsor: Erasmus Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study tracks lung function and symptoms in fibrosis patients on nintedanib
Knowledge-focused TerminatedThis study looked at 88 adults with connective tissue disease-related lung scarring who were prescribed nintedanib. Researchers measured changes in lung function and tracked cough and breathlessness using a questionnaire over 24 months. The goal was to see if improvements in lung…
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Why do some COPD patients get less benefit from exercise? new study investigates
Knowledge-focused TerminatedThis study looked at why exercise training improves blood vessel function less in some people with COPD than in healthy individuals. Researchers measured blood vessel health before and after a 4-week exercise program in 69 participants, including COPD patients and healthy volunte…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Anesthesia drug study halted after just 3 patients
Knowledge-focused TerminatedThis study aimed to see if skipping a type of muscle relaxant during general anesthesia could lower the risk of serious lung complications in high-risk surgery patients. The trial was terminated early after enrolling only 3 participants, so no meaningful conclusions can be drawn.…
Phase: PHASE4 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Inhaled cancer drug tested in smokers – early study halted
Knowledge-focused TerminatedThis early-stage study tested whether inhaling the cancer drug afatinib works as well as taking it by mouth. Four healthy adult smokers received both forms in separate sessions to compare drug levels in the blood and lungs. The study was terminated early, so the findings are limi…
Phase: PHASE1 • Sponsor: Petrov, Andrey • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Brain injury and ARDS: which breathing maneuver is safer?
Knowledge-focused TerminatedThis study compared two breathing techniques (CPAP and eSigh) in 18 patients with brain injury and acute respiratory distress syndrome (ARDS). The goal was to see which method better maintains oxygen levels in the brain without causing harm. The trial was terminated early, so fin…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New imaging technique could let doctors see lung Cancer's inner workings in real time
Knowledge-focused TerminatedThis early-phase study tested whether two optical imaging agents could be used during a bronchoscopy to visualize activated neutrophils and a cancer-related protein called c-MET in lung tumors. Five participants with lung cancer received the agents through a special catheter whil…
Phase: EARLY_PHASE1 • Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
COPD study investigates why patients struggle to fight lung infections
Knowledge-focused TerminatedThis study looked at whether a weak immune response to bacteria in COPD patients leads to more lung infections and flare-ups. Researchers collected sputum, blood, and nasal swabs from 23 hospitalized COPD patients during a flare-up and again 8 to 16 weeks later. The goal was to m…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Ventilator weaning study for obese patients halted early
Knowledge-focused TerminatedThis study tested if a special measurement called transpulmonary pressure could help obese patients with breathing failure get off ventilators sooner. Only 4 people took part before the study was stopped early. The goal was to reduce time on the ventilator and lower risks like in…
Phase: NA • Sponsor: University of Mississippi Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New program aims to help pregnant smokers quit for healthier babies
Knowledge-focused TerminatedThis study aimed to help low-income pregnant women stop smoking and make their homes smoke-free. Smoking during pregnancy raises the risk of cancer and can lead to low birth weight and other health problems for the baby. The program offered support and referrals to services durin…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Blood test may guide lung cancer treatment
Knowledge-focused TerminatedThis study aimed to see if immune cells in the blood match those inside lung tumors. Researchers hoped to find a simple blood test that could help doctors decide which patients might respond to immunotherapy. The study planned to enroll 22 people with early-stage lung cancer who …
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Gene study could personalize asthma inhalers for kids
Knowledge-focused TerminatedThis study looked at whether a variation in the PDE4 gene influences how well children with persistent asthma respond to the common rescue inhaler salbutamol. Researchers measured lung function before and after giving the drug and compared results across different gene types. The…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Cancer tissue collected within hours of death to unlock tumor secrets
Knowledge-focused TerminatedThis study aimed to collect tumor tissue from patients with lung, chest cavity, ovarian, or bladder cancers, or those who had adoptive cell therapy, within three hours after death. Participants received inpatient hospice care at the NIH Clinical Center. The goal was to analyze th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Lung cancer study aims to predict dangerous lung inflammation
Knowledge-focused TerminatedThis study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effe…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Virtual reality could help measure and treat cancer pain, study suggests
Knowledge-focused TerminatedThis study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Scientists hunt for genetic and environmental clues in rare lung disease
Knowledge-focused TerminatedThis study aimed to describe the features and natural history of idiopathic interstitial pneumopathy, a group of rare lung diseases, in both children and adults. Researchers planned to collect data from 1,600 participants, including medical history, imaging, and genetic tests, to…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New lung camera could replace needle biopsies
Knowledge-focused TerminatedThis study aimed to see if a tiny camera on a thin tube (bronchoscopy) could help doctors diagnose diffuse lung diseases without needing a surgical lung biopsy. The camera takes live microscopic images of the air sacs. The study was stopped early, but it involved 38 adults with c…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Microscope inside the lungs reveals hidden damage in two diseases
Knowledge-focused TerminatedThis study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study w…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Preterm Kids' lungs under the microscope: study halted early
Knowledge-focused TerminatedThis study aimed to track lung function in children born prematurely (before 37 weeks) aged 3 to 5 years, comparing them to full-term children. Researchers used breathing tests and samples to look for early signs of asthma and allergies. The study was terminated early, so results…
Sponsor: Stefania La Grutta, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Tiny study on steroid bone damage fizzles out
Knowledge-focused TerminatedThis study aimed to see if special CT scans could detect changes in bone density and bone marrow in people with asthma who take oral steroids. Only 2 people took part before the study was stopped early. The results are too limited to draw any conclusions.
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Lung cancer imaging study halted early
Knowledge-focused TerminatedThis pilot study aimed to see if combining PET and MRI scans could better show tumor differences in non-small cell lung cancer (NSCLC). Only 11 people were enrolled before the study was stopped early. The goal was to check if the imaging method was consistent when used by differe…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Blood test vs. needle biopsy: can a simple draw detect lung cancer mutations?
Knowledge-focused TerminatedThis study looked at whether a blood test (liquid biopsy) could find EGFR gene mutations in lung cancer patients as accurately as a standard tumor biopsy. Researchers planned to enroll 21 patients with advanced lung cancer who had not yet received treatment. The study was termina…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Sleep apnea machine tested for IPF lung health – but study stopped early
Knowledge-focused TerminatedThis study looked at whether using a CPAP machine at night could reduce abnormal acid reflux and lung inflammation in people with idiopathic pulmonary fibrosis (IPF) who also have sleep apnea. Only 7 people enrolled before the study was terminated early. The goal was to measure c…
Phase: NA • Sponsor: University of Arizona • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Asthma attack study halted: what we almost learned
Knowledge-focused TerminatedThis study aimed to uncover hidden causes of asthma attacks and how inhaled steroids work. Researchers planned to analyze sputum from 67 adults with severe asthma. However, the study was terminated early, so results are limited.
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Lung cancer immunotherapy duration study halted early
Knowledge-focused TerminatedThis study looked at how long to continue immunotherapy in people with advanced non-small cell lung cancer who had already responded well to treatment for 6 to 12 months. The goal was to see if stopping or continuing treatment made a difference in keeping the cancer from growing.…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Lung cancer video trial fails to reach goal
Knowledge-focused TerminatedThis study aimed to see if a culturally tailored educational video could help African American, Korean, and Chinese adults learn about lung cancer and screening. Researchers planned focus groups and interviews with 11 participants to understand barriers. The trial was terminated …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Cystic fibrosis study aims to build a research database, not test a cure
Knowledge-focused TerminatedThis study is for people with cystic fibrosis and their family members. Its goal is to collect medical information and biological samples during regular clinic visits. These will be stored and used by researchers to learn more about how cystic fibrosis affects the body and how it…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Scientists investigate why ventilators may worsen lung infections
Knowledge-focused TerminatedThis study looked at how mechanical ventilation (breathing machines) affects the energy centers (mitochondria) of immune cells in patients with severe lung infections and acute respiratory distress syndrome (ARDS). Researchers aimed to understand why some patients get worse despi…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Lung cancer Follow-Up study ends early – only 5 participants
Knowledge-focused TerminatedThis pilot study tested a program called SHAREDCare, where a navigator helps lung cancer survivors identify their needs and create a plan to address them. The goal was to improve follow-up care after cancer treatment. However, the study was terminated early and included only 5 pe…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Lung cancer drug levels under the microscope
Knowledge-focused TerminatedThis observational study looked at how much of the immunotherapy drug pembrolizumab stays in the blood of patients with advanced non-small cell lung cancer. Researchers measured drug levels and immune responses in 80 patients receiving pembrolizumab alone or with chemotherapy. Th…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Cancer drug interaction study halted after just one patient
Knowledge-focused TerminatedThis early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Tiny study uses PET scans to track cancer drug in tumors
Knowledge-focused TerminatedThis early-phase study aimed to use PET imaging to track how a new drug (BI 754111) spreads in the body and reaches tumors in people with advanced non-small cell lung cancer or head and neck cancer. Only 8 participants were planned, and the study was terminated early. The main go…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Tiny study on lung support in ARDS halted early
Knowledge-focused TerminatedThis study aimed to compare two ways of setting breathing machine pressure (PEEP) in patients with severe lung injury (ARDS). The goal was to see which method better protects the lungs and heart. Only 2 patients were enrolled before the study was stopped, so no meaningful results…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Scientists probe immune cells in pneumonia to unlock ARDS secrets
Knowledge-focused TerminatedThis study looked at how certain immune cells, called non-conventional T cells, behave in patients with severe pneumonia and acute respiratory distress syndrome (ARDS). Researchers collected blood and airway samples from 258 intensive care unit patients to track these cells over …
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Lung cancer gene study halted early
Knowledge-focused TerminatedThis study looked at the genetics of people with multiple lung tumors (multifocal lung adenocarcinoma). Researchers collected tissue and blood samples from 100 participants during surgery to analyze their DNA. The goal was to see if genetic information could help guide treatment …
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
AI stethoscope could spot lung disease patterns
Knowledge-focused TerminatedThis study tested whether artificial intelligence can detect and classify abnormal lung sounds in people with cystic fibrosis, COPD, or pulmonary fibrosis. Researchers recorded lung sounds with an electronic stethoscope during routine checkups and analyzed them using AI. The goal…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Smart band tracks COVID-19 breathing trouble
Knowledge-focused TerminatedThis study tested a special band called AirGo to monitor breathing patterns in hospitalized COVID-19 patients with respiratory failure. The goal was to see if the band could detect early signs of worsening breathing, helping doctors decide when to use a breathing tube. The study …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Water spray tested to protect seniors with lung disease from heat waves
Knowledge-focused TerminatedThis study aimed to see if spraying water on the body could help older adults with COPD stay cool during heat waves. Researchers planned to measure body temperature and lung function in a climate chamber. However, only one person took part before the study was stopped, so no mean…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Lung cancer biomarker study halted after enrolling only 22 patients
Knowledge-focused TerminatedThis study aimed to find genetic changes in lung tissue and blood that could predict how squamous cell lung cancer progresses. Researchers planned to collect samples from 200 patients undergoing lung procedures, but the study was stopped early with only 22 participants. No treatm…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Body clock may predict asthma attacks
Knowledge-focused TerminatedThis study looked at whether proteins that control our body's daily rhythms (clock proteins) can predict how severe asthma will get. Researchers monitored these proteins in the blood and sputum of 50 adults with severe eosinophilic asthma before and during treatment with mepolizu…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New MRI technique peers inside lungs of COPD patients after valve procedure
Knowledge-focused TerminatedThis study used a special type of MRI (called hyperpolarized xenon-129 MRI) to take detailed pictures of lung function in 27 people with COPD who were scheduled to receive endobronchial valve therapy as part of their normal care. The goal was to see how the lungs work before and …
Phase: PHASE1 • Sponsor: Xemed LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Breathing in a special gas reveals hidden lung damage in transplant patients
Knowledge-focused TerminatedThis study used a special MRI technique with a harmless gas called hyperpolarized xenon-129 to take detailed pictures of lung function in people who had a lung transplant. The goal was to see if this scan could detect early signs of chronic lung allograft dysfunction (CLAD), a co…
Sponsor: Xemed LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Early safety test of iCP-NI drug halted before completion
Knowledge-focused TerminatedThis early-phase study tested the safety and tolerability of an experimental drug called iCP-NI in 24 healthy adults. Participants received either the drug or a placebo by intravenous infusion. The trial was terminated, so no conclusions about effectiveness can be drawn.
Phase: PHASE1 • Sponsor: Cellivery Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:00 UTC
-
Ventilator showdown: which mode helps ICU patients breathe better?
Knowledge-focused TerminatedThis study looked at two different ways to use a breathing machine (ventilator) for patients in the intensive care unit who have dangerously low oxygen levels. The goal was to measure pressure inside the lungs with each method to see which might be safer or more effective. The st…
Phase: NA • Sponsor: University Hospital Bispebjerg and Frederiksberg • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:48 UTC
-
Asthma study aims to better understand uncontrolled disease in daily life
Knowledge-focused TerminatedThis study looked at adults with severe uncontrolled asthma in Germany to see how well their asthma was controlled over 12 months. Researchers used a simple questionnaire called AIRQ® to track symptoms, medication use, and doctor visits. The goal was to gather real-world informat…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:03 UTC
-
New E-Health system aims to keep tabs on chronic patients remotely
Knowledge-focused TerminatedThis pilot study tested an e-health system that uses tele-monitoring, tele-notification, and tele-coaching to help manage adults with at least two chronic conditions like heart failure, COPD, or diabetes. The goal was to see how well the system could detect health problems early.…
Phase: NA • Sponsor: Air Liquide Santé International • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:48 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused TerminatedThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC
-
Xenon gas MRI could spot lung transplant rejection early
Knowledge-focused TerminatedThis study tested a new type of MRI that uses inhaled xenon gas to create detailed images of the lungs. The goal was to see if it could detect early signs of chronic rejection in lung transplant recipients. Only 6 adults who had double lung transplants took part, and the study wa…
Phase: PHASE2 • Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:27 UTC